These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Interferon therapy for chronic hepatitis B. Asselah T; Lada O; Moucari R; Martinot M; Boyer N; Marcellin P Clin Liver Dis; 2007 Nov; 11(4):839-49, viii. PubMed ID: 17981231 [TBL] [Abstract][Full Text] [Related]
30. [Is there hope for hepatitis delta ?]. Guglielmi S; Frossard JL; Negro F Rev Med Suisse; 2016 Aug; 12(528):1415-1418. PubMed ID: 28675280 [TBL] [Abstract][Full Text] [Related]
31. HDV evolution-will viral resistance be an issue in HDV infection? Tabernero D; Cortese MF; Buti M; Rodriguez-Frias F Curr Opin Virol; 2018 Oct; 32():100-107. PubMed ID: 30415162 [TBL] [Abstract][Full Text] [Related]
32. Can We Predict Sustained Virologic Response to Interferon α Therapy in Patients With Chronic Hepatitis Delta Virus Infection? Scholtès C; Kumar R; Zoulim F Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2350-2. PubMed ID: 26254201 [No Abstract] [Full Text] [Related]
33. Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised study. Papadopoulos VP; Chrysagis DN; Protopapas AN; Goulis IG; Dimitriadis GT; Mimidis KP Med Sci Monit; 2009 Feb; 15(2):CR56-61. PubMed ID: 19179968 [TBL] [Abstract][Full Text] [Related]
34. Efficacy of pegylated interferon-α treatment for 24 months in chronic delta hepatitis and predictors of response. Karaca C; Soyer OM; Baran B; Ormeci AC; Gokturk S; Aydin E; Evirgen S; Akyuz F; Demir K; Besisik F; Kaymakoglu S Antivir Ther; 2013; 18(4):561-6. PubMed ID: 22976528 [TBL] [Abstract][Full Text] [Related]
35. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319 [TBL] [Abstract][Full Text] [Related]
36. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. Durantel D; Zoulim F J Hepatol; 2016 Apr; 64(1 Suppl):S117-S131. PubMed ID: 27084032 [TBL] [Abstract][Full Text] [Related]
37. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Gunsar F; Akarca US; Ersoz G; Kobak AC; Karasu Z; Yuce G; Ilter T; Batur Y Antivir Ther; 2005; 10(6):721-6. PubMed ID: 16218171 [TBL] [Abstract][Full Text] [Related]
38. Chronic hepatitis D at a standstill: where do we go from here? Ciancio A; Rizzetto M Nat Rev Gastroenterol Hepatol; 2014 Jan; 11(1):68-71. PubMed ID: 24019153 [TBL] [Abstract][Full Text] [Related]
39. Pathogenesis of and New Therapies for Hepatitis D. Koh C; Heller T; Glenn JS Gastroenterology; 2019 Jan; 156(2):461-476.e1. PubMed ID: 30342879 [TBL] [Abstract][Full Text] [Related]
40. Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options. Lempp FA; Ni Y; Urban S Nat Rev Gastroenterol Hepatol; 2016 Oct; 13(10):580-9. PubMed ID: 27534692 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]